FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378191481> ?p ?o ?g. }

• W4378191481 endingPage "e200175" @default.
• W4378191481 startingPage "e200175" @default.
• W4378191481 abstract "Background and Objectives Ulotaront (SEP-363856) is a trace amine-associated receptor 1 agonist with 5-HT 1A receptor agonist activity currently in phase 3 clinical development for the treatment of schizophrenia. In this exploratory, flexibly dosed study, ulotaront was evaluated for the treatment of Parkinson disease psychosis (PDP). Methods Patients with PDP requiring antipsychotic therapy were randomized, double-blind to ulotaront (25, 50, or 75 mg/d) or placebo. Mixed Model for Repeated Measures was used to assess change from baseline in the Scale for the Assessment of Positive Symptoms for Parkinson Disease (SAPS-PD) at 6 weeks (primary end point). Results The efficacy analysis sample comprised 38 patients (ulotaront, n = 24; placebo, n = 14). SAPS-PD total scores were numerically reduced in ulotaront-treated vs placebo-treated patients from week 1 to week 6: Least squares mean (95% confidence interval) difference in change from baseline at week 6 was −1.1 (−6.5, 4.3, p = 0.681). PDP symptom complete remission (≥100% improvement [reduction] from baseline in SAPS-PD total score) was observed in 25% of ulotaront-treated vs 0% of placebo-treated patients. SAPS-PD and Neuropsychiatric Inventory hallucinations subscales were numerically reduced vs placebo, and SAPS-PD total scores were reduced in patients with greater cognitive impairment (baseline Mini-Mental State Examination [MMSE] scores ≤24). Ulotaront improved Scales for Outcomes in Parkinson Disease Sleep Scale – Daytime Sleepiness scores ( p = 0.022). There was no worsening of Unified Parkinson Disease Rating Scale Part III motor score, MMSE, or vital signs. Adverse events (≥10%) with ulotaront vs placebo included hallucinations (24% vs 14%), confusional state (20% vs 14%), dizziness (16% vs 7%), nausea (12% vs 7%), and falls (12% vs 21%). Discussion In this exploratory pilot study, ulotaront may decrease PDP symptoms without worsening motor function, particularly in patients with cognitive impairment. Trial Registration Information ClinicalTrials.gov identifier: NCT02969369 ; submitted: November 17, 2016; study start date: December 31, 2016. Classification of Evidence This Class II study was an exploratory pilot study that was underpowered to detect a statistically significant difference between ulotaront and placebo in the treatment of patients with Parkinson disease psychosis without worsening motor function." @default.
• W4378191481 created "2023-05-26" @default.
• W4378191481 creator A5001103468 @default.
• W4378191481 creator A5007710677 @default.
• W4378191481 creator A5009117789 @default.
• W4378191481 creator A5020726985 @default.
• W4378191481 creator A5044000196 @default.
• W4378191481 creator A5047043019 @default.
• W4378191481 creator A5059530469 @default.
• W4378191481 creator A5060664922 @default.
• W4378191481 creator A5084126298 @default.
• W4378191481 creator A5088238884 @default.
• W4378191481 date "2023-05-25" @default.
• W4378191481 modified "2023-09-27" @default.
• W4378191481 title "Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT_1AAgonist, in Patients With Parkinson Disease Psychosis" @default.
• W4378191481 cites W1114757218 @default.
• W4378191481 cites W132813541 @default.
• W4378191481 cites W1969895941 @default.
• W4378191481 cites W1981706712 @default.
• W4378191481 cites W2006406145 @default.
• W4378191481 cites W2008560062 @default.
• W4378191481 cites W2011260714 @default.
• W4378191481 cites W2031740174 @default.
• W4378191481 cites W2042338589 @default.
• W4378191481 cites W2067807847 @default.
• W4378191481 cites W2075960947 @default.
• W4378191481 cites W2083220625 @default.
• W4378191481 cites W2088345696 @default.
• W4378191481 cites W2090101179 @default.
• W4378191481 cites W2094537992 @default.
• W4378191481 cites W2097646077 @default.
• W4378191481 cites W2107881620 @default.
• W4378191481 cites W2109069020 @default.
• W4378191481 cites W2110890724 @default.
• W4378191481 cites W2118538122 @default.
• W4378191481 cites W2122683614 @default.
• W4378191481 cites W2138883123 @default.
• W4378191481 cites W2153641048 @default.
• W4378191481 cites W2159155203 @default.
• W4378191481 cites W2168136369 @default.
• W4378191481 cites W2513283541 @default.
• W4378191481 cites W2579373654 @default.
• W4378191481 cites W2592445907 @default.
• W4378191481 cites W2786029268 @default.
• W4378191481 cites W2860035592 @default.
• W4378191481 cites W2889633769 @default.
• W4378191481 cites W2889655735 @default.
• W4378191481 cites W2898955001 @default.
• W4378191481 cites W2908548900 @default.
• W4378191481 cites W2921354076 @default.
• W4378191481 cites W2948985987 @default.
• W4378191481 cites W2964999518 @default.
• W4378191481 cites W2981269611 @default.
• W4378191481 cites W3007887826 @default.
• W4378191481 cites W3015204490 @default.
• W4378191481 cites W3031549057 @default.
• W4378191481 cites W3155391591 @default.
• W4378191481 cites W3213184078 @default.
• W4378191481 cites W4200032489 @default.
• W4378191481 cites W4200212552 @default.
• W4378191481 cites W4200449691 @default.
• W4378191481 cites W4254230094 @default.
• W4378191481 doi "https://doi.org/10.1212/cpj.0000000000200175" @default.
• W4378191481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37273942" @default.
• W4378191481 hasPublicationYear "2023" @default.
• W4378191481 type Work @default.
• W4378191481 citedByCount "3" @default.
• W4378191481 countsByYear W43781914812023 @default.
• W4378191481 crossrefType "journal-article" @default.
• W4378191481 hasAuthorship W4378191481A5001103468 @default.
• W4378191481 hasAuthorship W4378191481A5007710677 @default.
• W4378191481 hasAuthorship W4378191481A5009117789 @default.
• W4378191481 hasAuthorship W4378191481A5020726985 @default.
• W4378191481 hasAuthorship W4378191481A5044000196 @default.
• W4378191481 hasAuthorship W4378191481A5047043019 @default.
• W4378191481 hasAuthorship W4378191481A5059530469 @default.
• W4378191481 hasAuthorship W4378191481A5060664922 @default.
• W4378191481 hasAuthorship W4378191481A5084126298 @default.
• W4378191481 hasAuthorship W4378191481A5088238884 @default.
• W4378191481 hasBestOaLocation W43781914811 @default.
• W4378191481 hasConcept C118552586 @default.
• W4378191481 hasConcept C126322002 @default.
• W4378191481 hasConcept C138496976 @default.
• W4378191481 hasConcept C142724271 @default.
• W4378191481 hasConcept C15744967 @default.
• W4378191481 hasConcept C170493617 @default.
• W4378191481 hasConcept C204787440 @default.
• W4378191481 hasConcept C27081682 @default.
• W4378191481 hasConcept C2776412080 @default.
• W4378191481 hasConcept C2778938600 @default.
• W4378191481 hasConcept C2779727114 @default.
• W4378191481 hasConcept C2780494398 @default.
• W4378191481 hasConcept C71924100 @default.
• W4378191481 hasConcept C83849319 @default.
• W4378191481 hasConceptScore W4378191481C118552586 @default.
• W4378191481 hasConceptScore W4378191481C126322002 @default.
• W4378191481 hasConceptScore W4378191481C138496976 @default.
• W4378191481 hasConceptScore W4378191481C142724271 @default.

• next